Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.
TSI EDITOR |
2021-12-10
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.
TSI EDITOR |
12/09/2021
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.
TSI EDITOR |
2021-12-09
MINDCURE's iSTRYM Platform: Psychedelics Penetration Is Only The Beginning
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
TSI EDITOR |
2021-12-08
More Outstanding Results With Psychedelics Research, Even More Outstanding Value For Investors
GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.
TSI EDITOR |
2021-12-07
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Mydecine files a detailed patent application covering "multiple families of psilocin analogs."
TSI EDITOR |
2021-12-06
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research reports its Q3 for 2021 and announces VERY successful results from its Phase 2a trial for Treatment Resistant Depression (TRD).
TSI EDITOR |
2021-12-06
Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders
Novamind's new Salt Lake City clinic will specialize in treating substance abuse disorders.
TSI EDITOR |
2021-12-06
The 5 Best Values In Psychedelic Stocks
Psychedelic stocks have recently been punished by the market. The flip-side is that many well-capitalized companies now offer spectacular value propositions.
TSI EDITOR |
2021-12-03
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now